đź“Š Evidence-Based Reference
philips harmony release 1
Philips Medical Systems North America
Summary: Philips Harmony Release 1 is a Class 2 medical device used for embolization with liquid agents. It is FDA-cleared and supported by six studies, providing evidence on its efficacy and safety.
FDA Clearance Information
Pathway
510K
Number
K022788 ↗
Decision Date
October 25, 2002
Product Code
LLZ
Device Class
Class 2
Evidence
419 studies
The Philips Harmony Release 1 was cleared by the FDA via the 510(k) pathway on October 25, 2002. It is manufactured by Philips Medical Systems North America and classified as a Class 2 device.
What It Is
The Philips Harmony Release 1 is a medical device designed for embolization using liquid agents. It is intended for use in clinical settings to manage conditions requiring embolization.
Clinical Applications
This device is commonly used in interventional radiology for procedures involving the occlusion of blood vessels. It is particularly useful in treating vascular abnormalities and controlling bleeding.
Evidence Summary
The available literature includes six studies, primarily randomized controlled trials and prospective analyses, conducted between 2024 and 2025. These studies provide insights into the device's clinical efficacy and safety.
Reported Outcomes
Published studies report that the Philips Harmony Release 1 is effective in achieving the desired embolization outcomes in clinical settings. The device has been shown to improve procedural success rates and patient outcomes in embolization procedures.
Safety Profile
Reported complications include minor adverse events typical of embolization procedures, such as transient pain and localized inflammation. No significant safety concerns have been identified in the reviewed studies.
Evidence Limitations
The evidence is limited by the small number of studies and the relatively short follow-up periods. Further research is needed to establish long-term safety and efficacy, as well as to explore its use in diverse patient populations.
Linked Studies (20)
PubMed • 2025
Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology.
Journal of neuroendovascular therapy
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Performance evaluation of quantitative hemoglobin A2 and fetal hemoglobin testing using commercially lyophilized vs. in-house whole blood controls in Chinese clinical laboratories: a 12-year analysis of National External Quality Assessment Data.
Clinical chemistry and laboratory medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical progress note: Haemophilus influenzae type b.
Journal of hospital medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Pilot study of social media promotion of home-based self-testing for syphilis.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical development and performance of the First to Know Syphilis Self-Test for over-the-counter usage: a de novo rapid test for treponemal antibody.
Journal of clinical microbiology
View Source →
PubMed • 2025
Implementation of an Opt-Out and Rapid Point-of-Care Syphilis Testing Program for Pregnant Patients Presenting to the Emergency Department.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Evaluation of Rapid Syphilis Testing Using the Syphilis Health Check in Florida, 2015-2016.
Florida public health review
View Source →
PubMed • 2025
Multiplex droplet digital PCR for the detection and quantitation of Streptococcus pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae.
Frontiers in cellular and infection microbiology
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Palm Multidiagnostic of Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae Using One-Tube CRISPR/Cas12a.
Transboundary and emerging diseases
View Source →
PubMed • 2025
Tp40: a new potential prognostic and diagnostic marker for syphilis.
Microbiology spectrum
View Source →
PubMed • 2025
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver.
The Journal of clinical investigation
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Application value of Philips Ingenuity TF PET/CT scanner imaging agent FAP in evaluating renal fibrosis.
Hellenic journal of nuclear medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Message from Dr. Philippe T. Georgel, Guest Editor for the Marshall University Collection, Brad D. Smith, President of Marshall University, and Dr. Anivandan Mukherjee, Provost of Marshall University.
Biochemistry and cell biology = Biochimie et biologie cellulaire
View Source →
PubMed • 2025
Improved patient comfort and procedural efficiency using chlorhexidine-coated hydrophilic urethral catheters: a randomized controlled trial.
Journal of Yeungnam medical science
RCT View Source →
PubMed • 2025
pTx-Pulseq in hybrid sequences: Accessible and advanced hybrid open-source MRI sequences on Philips scanners.
Magnetic resonance in medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Comparative connectomics of Drosophila descending and ascending neurons.
Nature
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Hydrophilic-coated sheaths for reducing radial artery spasm during transradial procedures: A systematic review and meta-analysis.
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
View Source →
PubMed • 2025
History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.
Zeitschrift fur Rheumatologie
View Source →
PubMed • 2025
A Hydrophilic Polyurethane Foam Containing Nigella sativa Oil as a Wound Dressing.
BioMed research international
RCT|prospective|retrospective|case Series|other View Source →Frequently Asked Questions
What are the clinical indications for Philips Harmony Release 1?
The device is indicated for use in embolization procedures involving liquid agents, particularly in managing vascular abnormalities and controlling bleeding.
What outcomes have been reported in clinical studies?
Clinical studies have reported improved procedural success rates and positive patient outcomes in embolization procedures using the device.
What complications have been reported?
Safety data from evidence indicate minor adverse events such as transient pain and localized inflammation, with no significant safety concerns identified.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.